MCID: IRS003
MIFTS: 33

Iris Disease

Categories: Eye diseases

Aliases & Classifications for Iris Disease

MalaCards integrated aliases for Iris Disease:

Name: Iris Disease 12 15
Iris Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:240
MeSH 44 D007499
NCIt 50 C34737
UMLS 73 C0022078

Summaries for Iris Disease

MalaCards based summary : Iris Disease, also known as iris diseases, is related to aniridia 2 and traumatic glaucoma. An important gene associated with Iris Disease is PAX6 (Paired Box 6), and among its related pathways/superpathways is Mesodermal Commitment Pathway. The drugs Timolol and Ganciclovir have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Wikipedia : 76 In humans and most mammals and birds, the iris (plural: irides or irises) is a thin, circular structure... more...

Related Diseases for Iris Disease

Diseases related to Iris Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 aniridia 2 10.7 ELP4 PAX6
2 traumatic glaucoma 10.7 OPTN PHEX
3 scleral staphyloma 10.7 OPTN PAX6
4 chronic closed-angle glaucoma 10.7 OPTN PHEX
5 glaucoma, normal tension 10.6 LOXL1 OPTN
6 acute closed-angle glaucoma 10.6 OPTN PEX19
7 congenital aphakia 10.5 OPTN PAX6
8 glaucoma-related pigment dispersion syndrome 10.5 LOXL1 PITX2
9 granuloma inguinale 10.4 MRAP WT1
10 enthesopathy 10.4 MRAP PHEX
11 morgagni cataract 10.4 CRYAA PHEX
12 glaucoma, primary open angle 10.4 LOXL1 OPTN PHEX
13 penile disease 10.4 MRAP PEX19
14 anterior segment dysgenesis 1 10.4 PAX6 PITX2
15 conjunctival degeneration 10.3 CRYAA PAX6
16 pseudopapilledema 10.3 IGF2 PAX6
17 hemihyperplasia, isolated 10.3 IGF2 WT1
18 pinguecula 10.2 CRYAA PAX6
19 purulent endophthalmitis 10.2 MRAP OPTN
20 isolated aniridia 10.2 FOXC1 PAX6
21 congenital mesoblastic nephroma 10.1 IGF2 WT1
22 hereditary wilms' tumor 10.1 IGF2 PAX6 WT1
23 rhabdoid cancer 10.1 IGF2 WT1
24 wilms tumor 5 10.0 IGF2 PAX6 WT1
25 axenfeld-rieger syndrome, type 1 9.9 PAX6 PITX2
26 ritscher-schinzel syndrome 9.9 FOXC1 OPTN
27 blood group, globoside system 9.9 CRYAA MRAP OPTN
28 vernal conjunctivitis 9.9 LOXL1 OPTN
29 hallermann-streiff syndrome 9.9 IGF2 OPTN
30 axenfeld-rieger syndrome, type 3 9.8 FOXC1 PITX2
31 anterior segment dysgenesis 4 9.7 FOXC1 PITX2
32 cornea plana 9.7 FOXC1 PITX2
33 rubeosis iridis 9.6 CRYAA IGF2
34 intestinal atresia 9.6 FOXC1 PAX6 PITX2
35 persistent hyperplastic primary vitreous 9.6 FOXC1 PAX6 PITX2
36 anterior segment dysgenesis 9.5 FOXC1 PAX6 PITX2
37 peters-plus syndrome 9.5 FOXC1 PAX6 PITX2
38 lens disease 9.5 CRYAA OPTN PAX6 PEX19 PHEX
39 phacogenic glaucoma 9.5 CRYAA LOXL1 OPTN PEX19 PHEX
40 hydrophthalmos 9.5 FOXC1 OPTN PITX2
41 axenfeld-rieger syndrome, type 2 9.4 FOXC1 OPTN PITX2
42 primary congenital glaucoma 9.4 FOXC1 OPTN PITX2
43 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 9.3 ELP4 FSHB IGF2 PAX6 WT1
44 cataract 9.2 CRYAA ELP4 LOXL1 PAX6 PITX2
45 glaucoma 3, primary congenital, a 9.2 FOXC1 OPTN PAX6 PITX2
46 axenfeld-rieger syndrome 9.2 FOXC1 OPTN PAX6 PITX2
47 intraocular pressure quantitative trait locus 9.2 FOXC1 LOXL1 OPTN PITX2
48 juvenile glaucoma 8.9 FOXC1 OPTN PAX6 PHEX PITX2
49 ewing sarcoma 8.6 FOXC1 IGF2 OPTN PAX6 WT1
50 aniridia 1 6.8 DCDC5 ELP4 FOXC1 FSHB IGF2 OPTN

Graphical network of the top 20 diseases related to Iris Disease:



Diseases related to Iris Disease

Symptoms & Phenotypes for Iris Disease

MGI Mouse Phenotypes related to Iris Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 WT1 FOXC1 FSHB IGF2 LOXL1 OPTN
2 digestive/alimentary MP:0005381 9.73 FOXC1 IGF2 LOXL1 PAX6 PHEX PITX2
3 reproductive system MP:0005389 9.5 WT1 FOXC1 FSHB IGF2 LOXL1 PAX6
4 respiratory system MP:0005388 9.1 WT1 FOXC1 IGF2 LOXL1 PAX6 PITX2

Drugs & Therapeutics for Iris Disease

Drugs for Iris Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 4,Phase 3,Not Applicable 26839-75-8 33624 5478
2
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
3
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
4
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
6
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
7
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
8
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
9
Certolizumab pegol Approved Phase 4 428863-50-7
10
Maleic acid Experimental Phase 4 110-16-7 444266
11
Bromfenac Approved July 1997 Phase 4 91714-94-2 60726
12 Adrenergic Agents Phase 4,Phase 3,Not Applicable
13 Adrenergic Antagonists Phase 4,Phase 3,Not Applicable
14 Adrenergic beta-Antagonists Phase 4,Phase 3,Not Applicable
15 Anti-Arrhythmia Agents Phase 4,Phase 3,Not Applicable
16 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antiviral Agents Phase 4,Phase 1,Phase 2,Not Applicable
22 Ganciclovir triphosphate Phase 4,Not Applicable
23 Nucleic Acid Synthesis Inhibitors Phase 4,Not Applicable
24 Carbonic Anhydrase Inhibitors Phase 4,Not Applicable
25 calcium heparin Phase 4
26 Analgesics Phase 4,Not Applicable
27 Analgesics, Non-Narcotic Phase 4,Not Applicable
28 Anti-Bacterial Agents Phase 4,Phase 1
29 Antibiotics, Antitubercular Phase 4,Phase 1
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antirheumatic Agents Phase 4,Not Applicable
35 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
44 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Adrenocorticotropic Hormone Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
2 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
3 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
4 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
6 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Recruiting NCT02769702 Phase 4 Acthar
7 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
8 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
9 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
10 A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
11 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
12 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
13 Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension Completed NCT01126203 Phase 3
14 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination Completed NCT00331240 Phase 3 travoprost/timolol fixed combination;placebo (artificial tears)
15 A Phase 3 Study to Evaluate ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Recruiting NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
16 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Active, not recruiting NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
17 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis Not yet recruiting NCT03576898 Phase 2, Phase 3 Topical ganciclovir versus oral valganciclovir versus placebo
18 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Terminated NCT00333996 Phase 2, Phase 3 Dexamethasone
19 Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis Completed NCT02482129 Phase 2 LME636 60 mg/mL ophthalmic solution;Dexamethasone 0.1% ophthalmic solution;LME636 Vehicle
20 A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis Completed NCT02406209 Phase 2 NS2;Prednisolone acetate ophthalmic suspension (1%)
21 Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Completed NCT02309385 Phase 1, Phase 2 8% Dexamethasone Sodium Phosphate - Visulex;15% Dexamethasone Sodium Phosphate - Visulex;Prednisolone Acetate (1%) Eye Drops
22 Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis Completed NCT00823173 Phase 2
23 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
24 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Completed NCT01936389 Phase 2 AR-12286
25 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
26 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Completed NCT00130637 Phase 2 Daclizumab
27 Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy Recruiting NCT03575130 Phase 2 Ripasudil eye drops;Optive eye drops
28 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) Active, not recruiting NCT02653391 Phase 1, Phase 2 Elamipretide 1.0% Ophthalmic Solution;Elamipretide 3.0% Ophthalmic Solution
29 Study of Ataluren in Patients With Aniridia Active, not recruiting NCT02647359 Phase 2 Ataluren;Placebo
30 Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti Completed NCT00876434 Phase 1 Sirolimus
31 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
32 Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma Unknown status NCT02679482
33 Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study Unknown status NCT02155478 Not Applicable
34 Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis Unknown status NCT01486693
35 Acute Anterior Uveitis: Psychic Burden and Pain Unknown status NCT01156285
36 LOXL1 Polymorphism in Pseudoexfoliation Syndrome Unknown status NCT01515735
37 The International Collaborative Exfoliation Syndrome Treatment Study Unknown status NCT00804115 Not Applicable Latanoprost with Pilocarpine vs Timolol or Cosopt
38 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty Unknown status NCT00744796 Not Applicable
39 Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome Unknown status NCT01455168
40 Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT02020044 Not Applicable
41 The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure Completed NCT02165631
42 Adherence With Fixed Versus Unfixed Glaucoma Therapy Completed NCT01281020
43 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed NCT00121147 Not Applicable Travatan;Azopt;Alphagan P
44 Micropulse Laser Trabeculoplasty as Adjunctive Treatment in Patients With Pseudoexfoliation Glaucoma Completed NCT03483402 Not Applicable
45 Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis Completed NCT01647529 Not Applicable Ganciclovir
46 Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty Completed NCT00485108 Not Applicable prednisolone 1%;ketorolac 0.5%;Artificial Tears (Methyl cellulose drops)
47 PEMF: an Adjunct Therapy for Anterior Uveitis Completed NCT01154010 Not Applicable
48 Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome Completed NCT01298895
49 Aqueous Humor Dynamics and Hypertensive Uveitis Completed NCT02765308
50 Early Diagnosis in Glaucoma With GDxVcc Completed NCT01022281

Search NIH Clinical Center for Iris Disease

Cochrane evidence based reviews: iris diseases

Genetic Tests for Iris Disease

Anatomical Context for Iris Disease

MalaCards organs/tissues related to Iris Disease:

41
Eye, Endothelial, Retina, Testes

Publications for Iris Disease

Variations for Iris Disease

Expression for Iris Disease

Search GEO for disease gene expression data for Iris Disease.

Pathways for Iris Disease

Pathways related to Iris Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ELP4 FOXC1 PAX6 PITX2

GO Terms for Iris Disease

Cellular components related to Iris Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.23 CRYAA ELP4 FOXC1 OPTN PAX6 PEX19

Biological processes related to Iris Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 FOXC1 FSHB IGF2 PAX6 PITX2 WT1
2 in utero embryonic development GO:0001701 9.65 FOXC1 IGF2 PITX2
3 skeletal system development GO:0001501 9.58 FOXC1 IGF2 PHEX
4 animal organ morphogenesis GO:0009887 9.54 IGF2 PAX6 PITX2
5 eye development GO:0001654 9.49 FOXC1 PAX6
6 pituitary gland development GO:0021983 9.46 PAX6 PITX2
7 positive regulation of DNA binding GO:0043388 9.43 FOXC1 PITX2
8 iris morphogenesis GO:0061072 9.26 PAX6 PITX2
9 lacrimal gland development GO:0032808 9.16 FOXC1 PAX6
10 blood vessel development GO:0001568 9.13 FOXC1 LOXL1 PAX6
11 camera-type eye development GO:0043010 8.92 FOXC1 PAX6 PITX2 WT1

Sources for Iris Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....